Sarepta Therapeutics, Inc.
SRPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11,560 | $8,910 | $11,346 | $7,318 |
| - Cash | $1,103 | $428 | $967 | $2,116 |
| + Debt | $1,343 | $1,397 | $1,617 | $1,138 |
| Enterprise Value | $11,800 | $9,878 | $11,996 | $6,340 |
| Revenue | $1,902 | $1,243 | $933 | $702 |
| % Growth | 53% | 33.3% | 32.9% | – |
| Gross Profit | $1,583 | $1,093 | $793 | $605 |
| % Margin | 83.2% | 87.9% | 85% | 86.2% |
| EBITDA | $333 | -$439 | -$582 | -$317 |
| % Margin | 17.5% | -35.3% | -62.4% | -45.2% |
| Net Income | $235 | -$536 | -$703 | -$419 |
| % Margin | 12.4% | -43.1% | -75.4% | -59.7% |
| EPS Diluted | 2.34 | -5.8 | -8.03 | -5.15 |
| % Growth | 140.3% | 27.8% | -55.9% | – |
| Operating Cash Flow | -$206 | -$501 | -$325 | -$443 |
| Capital Expenditures | -$137 | -$87 | -$32 | -$38 |
| Free Cash Flow | -$343 | -$588 | -$358 | -$482 |